المؤلفون: Yau, T., Park, J. W., Finn, R. S., Cheng, A. L., Mathurin, Philippe, Edeline, Julien, Kudo, M., Harding, J. J., Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, L., Schott, E., Choo, S. P., Kelley, R. K., Sieghart, W., Assenat, Eric, Zaucha, R., Furuse, J., Abou-Alfa, G. K., El-Khoueiry, A. B., Melero, I., Begic, D., Chen, G., Neely, J., Wisniewski, T., Tschaika, M., Sangro, B.

المساهمون: Université de Lille, Inserm, CHU Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, CRLCC Eugène Marquis CRLCC, Hôpital de la Croix-Rousse CHU - HCL, CHU Pitié-Salpêtrière AP-HP, Hôpital Saint Eloi CHRU Montpellier

العلاقة: Lancet Oncol; http://hdl.handle.net/20.500.12210/100999Test

الإتاحة: https://doi.org/20.500.12210/100999Test
https://hdl.handle.net/20.500.12210/100999Test

المؤلفون: Vogel, A, Sahai, V, Hollebecque, A, Vaccaro, G M, Melisi, D, Al Rajabi, R M, Paulson, A S, Borad, M J, Gallinson, D, Murphy, A G, Oh, D-Y, Dotan, E, Catenacci, D V, Van Cutsem, E, Lihou, C F, Zhen, H, Veronese, M L, Abou-Alfa, G K

المصدر: ESMO Open ; ISSN:2059-7029 ; Volume:9 ; Issue:6

مصطلحات موضوعية: fibroblast growth factor receptor, intrahepatic cholangiocarcinoma, next-generation sequencing, pemigatinib, precision medicine, targeted therapy

العلاقة: https://doi.org/10.1016/j.esmoop.2024.103488Test; https://pubmed.ncbi.nlm.nih.gov/38838500Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11190465Test/

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.103488Test
https://pubmed.ncbi.nlm.nih.gov/38838500Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11190465Test/

المؤلفون: Vogel, A., Chan, S. L., Furuse, J., Tak, W. Y., Masi, G., Varela Calvo, María, Kim, J. H., Tanasanvimon, S., Reig Monzon, M. E., Dayyani, F., Makowsky, M., Marcovitz, M., Negro, A., Abou-Alfa, G. K.

المصدر: WOS:000897943700081

العلاقة: Annals of Oncology; http://dx.doi.org/10.1016/j.annonc.2022.10.115Test; http://hdl.handle.net/10651/68157Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.10.115Test
http://hdl.handle.net/10651/68157Test

المؤلفون: Ducreux, M., Abou-Alfa, G. K., Bekaii-Saab, T., Berlin, J., Cervantes, A., de Baere, T., Eng, C., Galle, P., Gill, S., Gruenberger, T., Haustermans, K., Lamarca, Angela, Laurent-Puig, P., Llovet, J. M., Lordick, F., Macarulla, T., Mukherji, D., Muro, K., Obermannova, R., O'Connor, J. M., O'Reilly, E. M., Osterlund, P., Philip, P., Prager, G., Ruiz-Garcia, E., Sangro, B., Seufferlein, T., Tabernero, J., Verslype, C., Wasan, H., Van Cutsem, E.

المساهمون: Université Paris-Saclay, Gustave Roussy, Villejuif, France.

العلاقة: https://dx.doi.org/10.1016/j.esmoop.2023.101567Test; Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO open. 2023 May 30;8(3):101567. PubMed PMID: 37263081. Pubmed Central PMCID: PMC10245111. Epub 2023/06/02. eng.; http://hdl.handle.net/10541/626340Test; ESMO Open

الإتاحة: https://doi.org/10.1016/j.esmoop.2023.101567Test
http://hdl.handle.net/10541/626340Test

المؤلفون: Abou-Alfa, G. K., Borbath, I., Goyal, L., Lamarca, Angela, Macarulla, T., Oh, D. Y., Roychowdhury, S., Sadeghi, S., Shroff, R. T., Li, A., Soto, J., Avogadri, F., Dambkowski, C. L., Javle, M. M.

المساهمون: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

العلاقة: Abou-Alfa GK, Borbath I, Goyal L, Lamarca A, Macarulla T, Oh DY, et al. PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304925.; http://hdl.handle.net/10541/625831Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4171Test
http://hdl.handle.net/10541/625831Test

المؤلفون: Abou-Alfa, G K, Qin, S, Ryoo, B-Y, Lu, S-N, Yen, C-J, Feng, Y-H, Lim, H Y, Izzo, F, Colombo, M, Sarker, D, Bolondi, L, Vaccaro, G, Harris, W P, Chen, Z, Hubner, R A, Meyer, T, Sun, W, Harding, J J, Hollywood, E M, Ma, J, Wan, P J, Ly, M, Bomalaski, J, Johnston, A, Lin, C-C, Chao, Y, Chen, L-T

المصدر: Abou-Alfa , G K , Qin , S , Ryoo , B-Y , Lu , S-N , Yen , C-J , Feng , Y-H , Lim , H Y , Izzo , F , Colombo , M , Sarker , D , Bolondi , L , Vaccaro , G , Harris , W P , Chen , Z , Hubner , R A , Meyer , T , Sun , W , Harding , J J , Hollywood , E M , Ma , J , Wan , P J , Ly , M , Bomalaski , J , ....

الإتاحة: https://doi.org/10.1093/annonc/mdy101Test
https://kclpure.kcl.ac.uk/portal/en/publications/3b263c4b-c9df-4960-803c-33418a64e03dTest

المؤلفون: Greten T. F., Abou-Alfa G. K., Cheng A. -L., Duffy A. G., El-Khoueiry A. B., Finn R. S., Galle P. R., Goyal L., He A. R., Kaseb A. O., Kelley R. K., Lencioni R., Lujambio A., Mabry Hrones D., Pinato D. J., Sangro B., Troisi R. I., Wilson Woods A., Yau T., Zhu A. X., Melero I.

المساهمون: Greten, T. F., Abou-Alfa, G. K., Cheng, A. -L., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., Kelley, R. K., Lencioni, R., Lujambio, A., Mabry Hrones, D., Pinato, D. J., Sangro, B., Troisi, R. I., Wilson Woods, A., Yau, T., Zhu, A. X., Melero, I.

مصطلحات موضوعية: antineoplastic protocol, guidelines as topic, immunotherapy, liver neoplasms

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34518290; info:eu-repo/semantics/altIdentifier/wos/WOS:000697845700001; volume:9; issue:9; firstpage:e002794; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; https://hdl.handle.net/11568/1113401Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85115015817

الإتاحة: https://doi.org/10.1136/jitc-2021-002794Test
https://hdl.handle.net/11568/1113401Test

المؤلفون: Vogel A., Rimassa L., Sun H. -C., Abou-Alfa G. K., El-Khoueiry A., Pinato D. J., Sanchez Alvarez J., Daigl M., Orfanos P., Leibfried M., Blanchet Zumofen M. -H., Gaillard V. E., Merle P.

المساهمون: Vogel, A., Rimassa, L., Sun, H. -C., Abou-Alfa, G. K., El-Khoueiry, A., Pinato, D. J., Sanchez Alvarez, J., Daigl, M., Orfanos, P., Leibfried, M., Blanchet Zumofen, M. -H., Gaillard, V. E., Merle, P.

مصطلحات موضوعية: Atezolizumab, Cancer immunotherapy, Hepatocellular carcinoma, Meta-analysis

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34239810; info:eu-repo/semantics/altIdentifier/wos/WOS:000652268400001; volume:10; issue:3; firstpage:240; lastpage:248; numberofpages:9; journal:LIVER CANCER; http://hdl.handle.net/11579/127576Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107476833

الإتاحة: https://doi.org/10.1159/000515302Test
http://hdl.handle.net/11579/127576Test

المؤلفون: Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., Harris, W. P., Murphy, A. G., Oh, D. Y., Whisenant, J. R., Chamberlain, C. X., Jiang, L., Gliser, C., Pandya, S. S., Valle, Juan W, Zhu, A. X.

المساهمون: Memorial Sloan Kettering Cancer Center & Weill Medical College at Cornell University, New York, NY

العلاقة: https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4069Test; Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. Vol. 39, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 4069–4069.; http://hdl.handle.net/10541/624864Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2021.39.15_suppl.4069Test
http://hdl.handle.net/10541/624864Test

المؤلفون: Valle, Juan W, Bibeau, K., Cho, Y. H., Ren, H. B., Feliz, L., Lihou, C. F., Abou-Alfa, G. K.

المساهمون: University of Manchester and Christie Hospital NHS Foundation Trust, Manchester

العلاقة: https://dx.doi.org/10.1200/JCO.2021.39.3_suppl.276Test; Valle JW, Bibeau K, Cho Y, Ren H, Féliz L, Lihou CF, et al. Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib. JCO. 2021 Jan 20;39(3_suppl):276–276.; http://hdl.handle.net/10541/623997Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2021.39.3_suppl.276Test
http://hdl.handle.net/10541/623997Test